Abstract
The cumulative cardiac toxicity of the anthracycline antibiotics and their propensity to produce severe tissue injury following extravasation from a peripheral vein during intravenous administration remain significant problems in clinical oncologic practice. Understanding of the free radical metabolism of these drugs and their interactions with iron proteins led to the development of dexrazoxane, an analogue of EDTA with intrinsic antineoplastic activity as well as strong iron binding properties, as both a prospective cardioprotective therapy for patients receiving anthracyclines and as an effective treatment for anthracycline extravasations. In this review, the molecular mechanisms by which the anthracyclines generate reactive oxygen species and interact with intracellular iron are examined to understand the cardioprotective mechanism of action of dexrazoxane and its ability to protect the subcutaneous tissues from anthracycline-induced tissue necrosis.
Keywords: Dexrazoxane, anthracycline, doxorubicin, oxidative stress, iron, chelator, cardiac toxicity, extravasation injury, cumulative cardiac toxicity, antineoplastic activity, oxygen species, tissue necrosis, daunorubicin, non-Hodgkin’s lymphoma, tissue injury.
Current Pharmaceutical Biotechnology
Title:Dexrazoxane for the Prevention of Cardiac Toxicity and Treatment of Extravasation Injury from the Anthracycline Antibiotics
Volume: 13 Issue: 10
Author(s): James H. Doroshow
Affiliation:
Keywords: Dexrazoxane, anthracycline, doxorubicin, oxidative stress, iron, chelator, cardiac toxicity, extravasation injury, cumulative cardiac toxicity, antineoplastic activity, oxygen species, tissue necrosis, daunorubicin, non-Hodgkin’s lymphoma, tissue injury.
Abstract: The cumulative cardiac toxicity of the anthracycline antibiotics and their propensity to produce severe tissue injury following extravasation from a peripheral vein during intravenous administration remain significant problems in clinical oncologic practice. Understanding of the free radical metabolism of these drugs and their interactions with iron proteins led to the development of dexrazoxane, an analogue of EDTA with intrinsic antineoplastic activity as well as strong iron binding properties, as both a prospective cardioprotective therapy for patients receiving anthracyclines and as an effective treatment for anthracycline extravasations. In this review, the molecular mechanisms by which the anthracyclines generate reactive oxygen species and interact with intracellular iron are examined to understand the cardioprotective mechanism of action of dexrazoxane and its ability to protect the subcutaneous tissues from anthracycline-induced tissue necrosis.
Export Options
About this article
Cite this article as:
H. Doroshow James, Dexrazoxane for the Prevention of Cardiac Toxicity and Treatment of Extravasation Injury from the Anthracycline Antibiotics, Current Pharmaceutical Biotechnology 2012; 13 (10) . https://dx.doi.org/10.2174/138920112802273245
DOI https://dx.doi.org/10.2174/138920112802273245 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Puerarin: A Review on the Pharmacological Activity, Chemical Properties
and Pharmacokinetics of Main Isoflavonoid
The Natural Products Journal Sympathetic Nervous System in Patients with Sleep Related Breathing Disorders
Current Hypertension Reviews Repulsive Guidance Molecules (RGMs) and Their Potential Implication in Cancer as Co-receptor of BMPs
Current Signal Transduction Therapy Global Cerebral Ischemia: Synaptic and Cognitive Dysfunction
Current Drug Targets Lights and Shadows on Monoamine Oxidase Inhibition in Neuroprotective Pharmacological Therapies
Current Topics in Medicinal Chemistry Endocannabinoids in Liver Disease and Hepatic Encephalopathy
Current Pharmaceutical Design Structure Based Drug Design of Angiotensin-I Converting Enzyme Inhibitors
Current Medicinal Chemistry Dynamics of Toll-like Receptors Signaling in Skeletal Muscle Atrophy
Current Medicinal Chemistry The Adenine Nucleotide Translocator: A New Potential Chemotherapeutic Target
Current Drug Targets Gene Therapy for Lysosomal Storage Diseases: Progress, Challenges and Future Prospects
Current Pharmaceutical Design Arsenic Immunotoxicity and Immunomodulation by Phytochemicals: Potential Relations to Develop Chemopreventive Approaches
Recent Patents on Inflammation & Allergy Drug Discovery The Role of Obesity in Cardiomyopathy and Nephropathy
Current Pharmaceutical Design Determinants of Left Ventricular Hypertrophy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Antidiabetic Potential of Naturally Occurring Sesquiterpenes: A Review
Current Topics in Medicinal Chemistry Urotensin II: A Vascular Mediator in Health and Disease
Current Vascular Pharmacology Chlorpyrifos with Age-Dependent Effects in Cardiac Tissue of Male Rats
Current Molecular Pharmacology Mitochondria Damage in the Pathogenesis of Diabetic Retinopathy and in the Metabolic Memory Associated with its Continued Progression
Current Medicinal Chemistry Angiogenesis as a therapeutic target in breast cancer
Mini-Reviews in Medicinal Chemistry The Impact of Methodology and Confounding Variables on the Association Between Major Depression and Coronary Heart Disease: Review and Recommendations
Current Psychiatry Reviews Smoking and Cardiovascular System: Cellular Features of the Damage
Current Pharmaceutical Design